The Pharma Letter8h
The week in pharma: action, reaction and insight – week to November 15
Last week saw US pharma major AbbVie release disappointing Phase II trial results on its emraclidine in schizophrenia, which ...
The Punch Newspapers9h
Experts warn of diabetes crisis amid soaring drug prices
Medical experts have raised concerns over the soaring costs and scarcity of diabetes medications in Nigeria. They also revealed that the number of individuals living with diabetes in the country has ...
Dupixent® (dupilumab) sBLA Accepted for FDA Review for the Treatment of Chronic Spontaneous Urticaria (CSU)
Resubmission includes new pivotal data which confirm Dupixent significantly reduced itch and hive activity More than 300,000 people in the U.S. suffer from CSU that is inadequately controlled by ...
Daily10h
Sanofi, Regeneron Dupixent sBLA accepted for USFDA review for chronic spontaneous urticaria
Paris: Sanofi and Regeneron has announced that the US Food and Drug Administration (FDA) has accepted for review the ...
Daily11h
Sarclisa recommended for EU approval by CHMP to treat transplant-ineligible newly diagnosed multiple myeloma: Sanofi
Paris: Sanofi has announced that the European Medicines Agency (EMA)'s Committee for Medicinal Products for Human Use (CHMP) ...
LEADERSHIP Newspaper16h
10 Firms Close Shop Over Nigeria’s Harsh Economy In 1 Year
No fewer than 10 companies have shut down or relocated their operations from Nigeria due to the current economic challenges, ...